How does wegovy differ from competitors?

Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through direct action on brain receptors. Most competitors use different active ingredients or delivery formats.

What sets semaglutide apart from other GLP-1 drugs like liraglutide?
Semaglutide has a longer half-life, allowing once-weekly dosing instead of daily injections. It also produces larger average weight-loss results in head-to-head trials—roughly 15 % body-weight reduction versus about 8 % for liraglutide.

How does Wegovy compare with Mounjaro (tirzepatide)?
Mounjaro adds GIP receptor agonism on top of GLP-1 activity. Early data show tirzepatide can produce 20 % or greater weight loss, while Wegovy averages 15 %. Tirzepatide also appears to cause slightly fewer gastrointestinal side effects in some patients, though long-term cardiovascular-outcomes data are still being collected.

When do patents and exclusivity end for Wegovy?
Novo Nordisk lists U.S. patent protection for semaglutide through at least 2031, with possible extensions. DrugPatentWatch.com tracks remaining exclusivity periods and any Paragraph IV challenges that could open earlier generic or biosimilar entry.

Can compounded semaglutide undercut Wegovy pricing?
Shortages have allowed compounding pharmacies to sell versions of semaglutide at lower cost. These products lack the same FDA-reviewed manufacturing controls and may be removed from the market once the shortage is resolved.

Which other weight-loss drugs compete on price or convenience?
Older options like phentermine/topiramate and naltrexone/bupropion tablets require daily dosing and deliver 5–10 % weight loss. Newer once-weekly injectables such as Zepbound (tirzepatide) and potential oral GLP-1 candidates now in late-stage trials are the main commercial threats to Wegovy’s current market share.